Cargando…

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function

PURPOSE: Critically ill patients with preserved or increased renal function have been shown to be at risk of underexposure to meropenem. Although many meropenem population pharmacokinetic (PK) models have been published, there is no large prospective population PK study with rich sampling focusing o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gijsen, Matthias, Elkayal, Omar, Annaert, Pieter, Van Daele, Ruth, Meersseman, Philippe, Debaveye, Yves, Wauters, Joost, Dreesen, Erwin, Spriet, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754504/ https://www.ncbi.nlm.nih.gov/pubmed/35035223 http://dx.doi.org/10.2147/IDR.S343264

Ejemplares similares

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
por: Gijsen, Matthias, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study
por: Gijsen, Matthias, et al.
Publicado: (2021)

Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2023)

Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients
por: Van Daele, Ruth, et al.
Publicado: (2021)

Meropenem Stability in Human Plasma at −20 °C: Detailed Assessment of Degradation
por: Gijsen, Matthias, et al.
Publicado: (2021)

The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation
por: Mertens, Beatrijs, et al.
Publicado: (2022)

Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid
por: Van Daele, Ruth, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine
por: Gijsen, Matthias, et al.
Publicado: (2021)

Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
por: Kantasiripitak, Wannee, et al.
Publicado: (2020)

Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2022)

External Validation of the Augmented Renal Clearance Predictor in Critically Ill COVID-19 Patients
por: Huang, Chao-Yuan, et al.
Publicado: (2023)

Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
por: Goncalves-Pereira, João, et al.
Publicado: (2014)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults
por: Gastmans, Heleen, et al.
Publicado: (2022)

Can augmented renal clearance be detected using estimators of glomerular filtration rate?
por: Gijsen, Matthias, et al.
Publicado: (2020)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
por: Braune, Stephan, et al.
Publicado: (2018)

Reproducibility of fluid status measured by bioelectrical impedance analysis in healthy volunteers: a key requirement to monitor fluid status in the intensive care unit
por: Gijsen, Matthias, et al.
Publicado: (2021)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Aerobic exercise capacity in long-term survivors of critical illness: secondary analysis of the post-EPaNIC follow-up study
por: Van Aerde, Nathalie, et al.
Publicado: (2021)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children
por: Wang, Zeming, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study
por: Peeters, Bram, et al.
Publicado: (2018)

2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
por: Le, Jennifer, et al.
Publicado: (2023)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
por: Sanz Codina, Maria, et al.
Publicado: (2022)

A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation
por: Van Daele, Ruth, et al.
Publicado: (2021)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

Adrenocortical function during prolonged critical illness and beyond: a prospective observational study
por: Peeters, Bram, et al.
Publicado: (2018)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

2560. Individual Meropenem Epithelial Lining Fluid and Plasma PK/PD Target Attainment in Patients with Pneumonia
por: Rohani, Roxane, et al.
Publicado: (2023)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_571kim5pevo2kad181l4mpng4h